 Check-Cap Ltd. the Company or Check-Cap NASDAQ: CHEK NASDAQ: CHEKZ, a clinical stage medical diagnostics company advancing the development of the C-Scan, the first and only patient-friendly preparation-free screening test to detect polyps before they may transform into cancer, today announced that it has entered into a definitive agreement with several existing institutional investors for the exercise of certain outstanding warrants to purchase up to an aggregate of 16,054,223 of its ordinary shares at a reduced exercise price of 0.60 per share. The warrants being exercised were issued by Check-Cap on several dates from November 2017 through May 2020 and have exercise prices ranging from 15.00 to 0.80 per share. 